A newly discovered antibiotic has been shown to block the synthesis of bacterial cell walls via immutable targets, raising the prospect of a class of drugs that will not lose effect through the development of antimicrobial resistance. Clovibactin, isolated from soil bacteria, targets the cell wall precursor molecules lipid II, lipid III and undecaprenyl phosphate (C55PP), all of which have a pyrophosphate group in common.
An international study led by Nanyang Technological University in Singapore has designed and synthesized broad-spectrum antimicrobial polymers (AMPs) and demonstrated the safety and efficacy of two such agents against multidrug-resistant (MDR) bacteria in mouse models of sepsis.
HONG KONG Researchers from the Massachusetts Institute of Technology’s (MIT) research enterprise in Singapore, known as Singapore-MIT Alliance for Research and Technology (SMART), have found a way to not just reverse antibiotic resistance but also increase sensitivity in some bacteria, using hydrogen sulfide.
LONDON – Twenty-three pharma companies are joining forces in the AMR Action Fund and have raised $1 billion in new money for the clinical development of antibiotic drugs addressing the most resistant bacteria. Working with philanthropic backers, the fund aims to bring two to four new antibiotics through to approval by 2030.
Targeted therapy offers an opportunity for personalized medicine that's specific for a patient's tumor, but the hyper-focused treatment creates possibilities for cells to mutate and become resistant to the therapy.
RSS
